Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications
Abstract
:1. Introduction
2. Methodology
2.1. Data Sources
2.2. Study Selection Process
2.3. Inclusion Criteria
2.4. Exclusion Criteria
2.5. Data Extraction and Synthesis
2.6. Limitations
3. Mental Health Disorders and Corticosteroids
3.1. Depression
3.2. Bipolar Disorder
3.3. Mania
3.4. Schizophrenia
3.5. Anxiety Disorders
3.6. Post-Traumatic Stress Disorder (PTSD)
3.7. Eating Disorders (EDs)
3.8. Special Cases: Corticosteroid-Induced Psychosis During COVID-19
3.9. Summary of the Key Mechanisms
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Sharman, A.H.T. Corticosteroids. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554612/ (accessed on 15 June 2024).
- Casper, R.C. Depression and eating disorders. Depress. Anxiety 1998, 8, 96–104. [Google Scholar] [CrossRef]
- Ralph, C.R.; Tilbrook, A.J.; Tilbrook, A.J. INVITED REVIEW: The usefulness of measuring glucocorticoids for assessing animal welfare. J. Anim. Sci. 2016, 94, 457–470. [Google Scholar] [CrossRef] [PubMed]
- Gensler, L.S. Glucocorticoids: Complications to anticipate and prevent. Neurohospitalist 2013, 3, 92–97. [Google Scholar] [CrossRef] [PubMed]
- Qutob, R.A.-O.; Alhusaini, B.A.-O.; Aljarba, N.A.-O.; Alzaid, O.N.; Aljahili, N.A.; Alzahrani, K.S.; Sharaf, M.M.; Alghamdi, A.H.; Alaryni, A.A.; Alammari, Y.M.; et al. Public Awareness Regarding Corticosteroid Use and Side Effects: A Cross-Sectional Study in Riyadh, Saudi Arabia. Healthcare 2023, 11, 2747. [Google Scholar] [CrossRef]
- Alhammadi, N.A.; Mohammed Al Oudhah, S.M.; Mofareh Asiri, M.A.; Alshehri, M.A.; Almutairi, B.A.B.; Mohammed Abdullah Thalibah, A.; Asiri, F.N.M.; Alshahrani, A.S.A. Public awareness of side effects of systemic steroids in Asir region, Saudi Arabia. J. Fam. Med. Prim. Care 2023, 12, 1854–1858. [Google Scholar] [CrossRef]
- Fardet, L.; Nazareth, I.; Whitaker, H.J.; Petersen, I. Severe Neuropsychiatric Outcomes Following Discontinuation of Long-Term Glucocorticoid Therapy. J. Clin. Psychiatry 2013, 74, e281–e286. [Google Scholar] [CrossRef]
- Bachu, A.K.; Davis, V.; Abdulrahim, M.; Harbaugh, L.; Prasad, S.; Kotapati, V.P.; Srinivas, S. Corticosteroid-Induced Psychosis: A Report of Three Cases. Cureus 2023, 15, e39221. [Google Scholar] [CrossRef]
- Stephens, M.A.; Wand, G. Stress and the HPA axis: Role of glucocorticoids in alcohol dependence. Alcohol. Res. 2012, 34, 468–483. [Google Scholar]
- Brown, E.S.; Chandler, P.A. Mood and cognitive changes during systemic corticosteroid therapy. Prim. Care Companion J. Clin. Psychiatry 2001, 3, 17. [Google Scholar] [CrossRef]
- Williams, D.M. Clinical Pharmacology of Corticosteroids. Respir. Care 2018, 63, 655–670. [Google Scholar] [CrossRef]
- Morgan, J.; Lacey, J.H. Anorexia nervosa and steroid withdrawal. Int. J. Eat. Disord. 1996, 19, 213–215. [Google Scholar] [CrossRef]
- World Health Organisation (WHO). Mental Health. Available online: https://www.who.int/news-room/fact-sheets/detail/mental-health-strengthening-our-response (accessed on 10 April 2024).
- Nestler, E.J.; Barrot M Fau DiLeone, R.J.; DiLeone Rj Fau Eisch, A.J.; Eisch Aj Fau—Gold, S.J.; Gold Sj Fau—Monteggia, L.M.; Monteggia, L.M. Neurobiology of depression. Neuron 2002, 34, 13–25. [Google Scholar] [CrossRef] [PubMed]
- World Health Organisation (WHO). Depressive Disorder (Depression). Available online: https://www.who.int/news-room/fact-sheets/detail/depression (accessed on 10 April 2024).
- Gautam, S.; Jain, A.; Gautam, M.; Vahia, V.N.; Grover, S. Clinical Practice Guidelines for the management of Depression. Indian. J. Psychiatry 2017, 59, S34–S50. [Google Scholar] [CrossRef] [PubMed]
- O’Connor, E.A.; Whitlock, E.P.; Gaynes, B.; Beil, T.L. Screening for Depression in Adults and Older Adults in Primary Care: An Updated Systematic Review [Internet]; CTI—U.S. Preventive Services Task Force Evidence Syntheses, Formerly Systematic Evidence Reviews; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2009.
- Kamran, M.; Bibi, F.; Ur Rehman, A.; Morris, D.W. Major Depressive Disorder: Existing Hypotheses about Pathophysiological Mechanisms and New Genetic Findings. Genes 2022, 13, 646. [Google Scholar] [CrossRef] [PubMed]
- Ding, W.; Wang, L.; Li, L.; Li, H.; Wu, J.; Zhang, J.; Wang, J. Pathogenesis of depression and the potential for traditional Chinese medicine treatment. Front. Pharmacol. 2024, 15, 1407869. [Google Scholar] [CrossRef]
- Wray, N.R.; Ripke, S.; Mattheisen, M.; Trzaskowski, M.; Byrne, E.M.; Abdellaoui, A.; Adams, M.J.; Agerbo, E.; Air, T.M.; Andlauer, T.M.F.; et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat. Genet. 2018, 50, 668–681. [Google Scholar] [CrossRef]
- Anacker, C.; Zunszain, P.A.; Carvalho, L.A.; Pariante, C.M. The glucocorticoid receptor: Pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 2011, 36, 415–425. [Google Scholar] [CrossRef]
- Varghese, F.P.; Brown, E.S. The Hypothalamic-Pituitary-Adrenal Axis in Major Depressive Disorder: A Brief Primer for Primary Care Physicians. Prim. Care Companion J. Clin. Psychiatry 2001, 3, 151–155. [Google Scholar] [CrossRef]
- James, F.; Holland, E.F.; Donald, W.K. Holland-Frei Cancer Medicine, 6th ed.; Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, R.C., Jr., Gansler, T.S., Holland, J.F., Frei, E., III, Eds.; BC Decker: Hamilton, ON, USA, 2003. [Google Scholar]
- Sheehan, D.V.; Lecrubier Y Fau-Sheehan, K.H.; Sheehan Kh Fau-Amorim, P.; Amorim P Fau-Janavs, J.; Janavs J Fau-Weiller, E.; Weiller E Fau-Hergueta, T.; Hergueta T Fau-Baker, R.; Baker R Fau-Dunbar, G.C.; Dunbar, G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59, 22–33. [Google Scholar]
- Chen, J.; Wang, Z.Z.; Zhang, S.; Chu, S.F.; Mou, Z.; Chen, N.H. The effects of glucocorticoids on depressive and anxiety-like behaviors, mineralocorticoid receptor-dependent cell proliferation regulates anxiety-like behaviors. Behav. Brain Res. 2019, 362, 288–298. [Google Scholar] [CrossRef]
- Holsboer, F. The Corticosteroid Receptor Hypothesis of Depression. Neuropsychopharmacology 2000, 23, 477–501. [Google Scholar] [CrossRef] [PubMed]
- Pofi, R.; Caratti, G.; Ray, D.W.; Tomlinson, J.W. Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad? Endocr. Rev. 2023, 44, 975–1011. [Google Scholar] [CrossRef] [PubMed]
- Hatch, R.; Young, D.; Barber, V.; Griffiths, J.; Harrison, D.A.; Watkinson, P.A.-O. Anxiety, Depression and Post Traumatic Stress Disorder after critical illness: A UK-wide prospective cohort study. Crit. Care 2018, 22, 310. [Google Scholar] [CrossRef] [PubMed]
- National Health Service (NHS). Cushing’s Syndrome. Available online: https://www.nhs.uk/conditions/cushings-syndrome/ (accessed on 10 June 2024).
- Ardayfio, P.; Kim, K.S. Anxiogenic-like effect of chronic corticosterone in the light-dark emergence task in mice. Behav. Neurosci. 2006, 120, 249–256. [Google Scholar] [CrossRef] [PubMed]
- Sonino, N.; Fava, G.A.; Raffi, A.R.; Boscaro, M.; Fallo, F. Clinical correlates of major depression in Cushing’s disease. Psychopathology 1998, 31, 302–306. [Google Scholar] [CrossRef]
- Zielinski, T.A.; Brown, E.S.; Nejtek, V.A.; Khan, D.A.; Moore, J.J.; Rush, A.J. Depression in Asthma: Prevalence and Clinical Implications. Prim. Care Companion J. Clin. Psychiatry 2000, 2, 153–158. [Google Scholar] [CrossRef]
- Caulfield, J.I. Anxiety, depression, and asthma: New perspectives and approaches for psychoneuroimmunology research. Brain Behav. Immun. Health 2021, 18, 100360. [Google Scholar] [CrossRef]
- Dehdar, K.; Raoufy, M.R. Effects of inhaled corticosteroids on brain volumetry, depression and anxiety-like behaviors in a rat model of asthma. Respir. Physiol. Neurobiol. 2023, 315, 104121. [Google Scholar] [CrossRef]
- Wolkowitz, O.M.; Lupien, S.J.; Bigler, E.; Levin, R.B.; Canick, J. The “steroid dementia syndrome”: An unrecognized complication of glucocorticoid treatment. Ann. N. Y. Acad. Sci. 2004, 1032, 191–194. [Google Scholar] [CrossRef]
- Savas, M.; Vinkers, C.H.; Rosmalen, J.G.; Hartman, C.A.; Wester, V.L.; Van Den Akker, E.L.; Iyer, A.M.; McEwen, B.S.; Van Rossum, E.F. Systemic and local corticosteroid use is associated with reduced executive cognition, and mood and anxiety disorders. Neuroendocrinology 2020, 110, 282–291. [Google Scholar] [CrossRef]
- Dehdar, K.; Mooziri, M.; Samii Moghaddam, A.; Salimi, M.; Nazari, M.; Dehghan, S.; Jamaati, H.; Salimi, A.; Raoufy, M.R. Corticosteroid treatment attenuates anxiety and mPFC-amygdala circuit dysfunction in allergic asthma. Life Sci. 2023, 315, 121373. [Google Scholar] [CrossRef] [PubMed]
- Koning, A.-S.C.A.M.; van der Meulen, M.; Schaap, D.; Satoer, D.D.; Vinkers, C.H.; van Rossum, E.F.C.; van Furth, W.R.; Pereira, A.M.; Meijer, O.C.; Dekkers, O.M. Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 2023, 109, e1442–e1451. [Google Scholar] [CrossRef] [PubMed]
- Anil Kumar, B.N.; Grover, S. Cushing’s Syndrome Masquerading as Treatment Resistant Depression. Indian. J. Psychol. Med. 2016, 38, 246–248. [Google Scholar] [CrossRef] [PubMed]
- Hill, A.R.; Spencer-Segal, J.L. Glucocorticoids and the Brain after Critical Illness. Endocrinology 2021, 162, bqaa242. [Google Scholar] [CrossRef] [PubMed]
- National Institute of Mental Health. Bipolar Disorder. Available online: https://www.nimh.nih.gov/health/topics/bipolar-disorder (accessed on 25 August 2024).
- Datto, C.; Pottorf, W.J.; Feeley, L.; LaPorte, S.; Liss, C. Bipolar II compared with bipolar I disorder: Baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Ann. Gen. Psychiatry 2016, 15, 9. [Google Scholar] [CrossRef]
- Association, A.P. What Are Bipolar Disorders? Available online: https://www.psychiatry.org/patients-families/bipolar-disorders/what-are-bipolar-disorders (accessed on 25 August 2024).
- Post, R.M. The impact of bipolar depression. J. Clin. Psychiatry 2005, 66, 5–10. [Google Scholar]
- Proudfoot, J.; Whitton, A.; Parker, G.; Doran, J.; Manicavasagar, V.; Delmas, K. Triggers of mania and depression in young adults with bipolar disorder. J. Affect. Disord. 2012, 143, 196–202. [Google Scholar] [CrossRef]
- Dagani, J.; Signorini, G.; Nielssen, O.; Bani, M.; Pastore, A.; Girolamo, G.; Large, M. Meta-analysis of the Interval between the Onset and Management of Bipolar Disorder. Can. J. Psychiatry 2017, 62, 247–258. [Google Scholar] [CrossRef]
- Gutiérrez-Arango, F.; Anmella, G.; Hidalgo-Mazzei, D.; Gomes-da-Costa, S.; Gil-Badenes, J.; Marco-Hernández, J.; Espinosa, G.; Colomer, L.; Baldaquí, N.; Pujal, E.; et al. Bipolar disorder and Susac syndrome: A case report. Int. Clin. Psychopharmacol. 2021, 36, 305–309. [Google Scholar] [CrossRef]
- He, Q.; Hu, X.; Cheng, L.; Zhu, Y.; Ling, C. A Case of Cushing Disease Masked by Symptoms of Bipolar Disorder. Neuro Endocrinol. Lett. 2020, 41, 345–349. [Google Scholar]
- Wu, Q.; Dalman, C.; Karlsson, H.; Lewis, G.; Osborn, D.P.J.; Gardner, R.; Hayes, J.F. Childhood and Parental Asthma, Future Risk of Bipolar Disorder and Schizophrenia Spectrum Disorders: A Population-Based Cohort Study. Schizophr. Bull. 2019, 45, 360–368. [Google Scholar] [CrossRef]
- El Moussaoui, N. Secondary Mania in Older Adults: A case report and review of literature. Eur. Psychiatry 2023, 66, S707. [Google Scholar] [CrossRef]
- Lesko, A.; Kalafat, N.; Afreen, M. Four Case Reports of Acute Psychosis Secondary to Low Doses of Prednisone/Prednisolone. Cureus 2021, 13, e20853. [Google Scholar] [CrossRef] [PubMed]
- King, J.A.-O.; Elliott, T.; Pitman, A. Steroid-induced mania in a patient with previously well-controlled organic bipolar 1-like affective disorder secondary to acquired brain injury: Case report and literature review. Discov. Ment. Health 2024, 4, 8. [Google Scholar] [CrossRef]
- Panwar, V.; Lassi, K. Stable Bipolar Patient Switched to Mania following Clinical Doses of Prednisone. Case Rep. Psychiatry 2011, 2011, 797658. [Google Scholar] [CrossRef] [PubMed]
- Deorah, N. Mood Disorders Associated with Glucocorticoid Therapy: Causes, Mechanisms, and Remediation. Int. J. High Sch. Res. 2022, 4, 16–27. [Google Scholar] [CrossRef]
- Merrill, W. Case 35-1998: Use of lithium to prevent corticosteroid-induced mania. N. Engl. J. Med. 1999, 340, 1123. [Google Scholar] [CrossRef]
- Preda, A.; Fazeli, A.; McKay, B.G.; Bowers, M.B.; Mazure, C.M. Lamotrigine as prophylaxis against steroid-induced mania. J. Clin. Psychiatry 1999, 60, 708–709. [Google Scholar] [CrossRef]
- Sachs, G.S.; Nierenberg, A.A.; Calabrese, J.R.; Marangell, L.B.; Wisniewski, S.R.; Gyulai, L.; Friedman, E.S.; Bowden, C.L.; Fossey, M.D.; Ostacher, M.J.; et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 2007, 356, 1711–1722. [Google Scholar] [CrossRef]
- Dailey, M.W.; Saadabadi, A. Mania. Int. Encycl. Soc. Behav. Sci. Second Ed. 2023, 484–489. [Google Scholar] [CrossRef]
- Manji, H.K.; Quiroz Ja Fau-Payne, J.L.; Payne Jl Fau-Singh, J.; Singh J Fau-Lopes, B.P.; Lopes Bp Fau-Viegas, J.S.; Viegas Js Fau-Zarate, C.A.; Zarate, C.A. The underlying neurobiology of bipolar disorder. World Psychiatry 2003, 2, 136–146. [Google Scholar] [PubMed]
- Wu, Y.; Su, Y.A.-O.; Zhu, L.; Li, J.; Si, T.A.-O. Advances in functional MRI research in bipolar disorder: From the perspective of mood states. Gen. Psychiatry 2024, 37, e101398. [Google Scholar] [CrossRef] [PubMed]
- Jansen, K.; Ores, L.d.C.; Cardoso, T.d.A.; Lima, R.d.C.; Souza, L.D.d.M.; Magalhães, P.V.d.S.; Pinheiro, R.T.; da Silva, R.A. Prevalence of episodes of mania and hypomania and associated comorbidities among young adults. J. Affect. Disord. 2011, 130, 328–333. [Google Scholar] [CrossRef] [PubMed]
- Singh, M.; Agarwal, V.; Jindal, D.; Pancham, P.; Agarwal, S.; Mani, S.; Tiwari, R.K.; Das, K.; Alghamdi, B.S.; Abujamel, T.S.; et al. Recent Updates on Corticosteroid-Induced Neuropsychiatric Disorders and Theranostic Advancements through Gene Editing Tools. Diagnostics 2023, 13, 337. [Google Scholar] [CrossRef] [PubMed]
- World Health Organisation (WHO). Schizophrenia. Available online: https://www.who.int/news-room/fact-sheets/detail/schizophrenia (accessed on 15 July 2024).
- Black, D.; Grant, J. The Essential Companion to the Diagnostic and Statistical Manual of Mental Disorders. Available online: https://www.appi.org/Products/DSM-Library/DSM-5-Guidebook (accessed on 15 July 2024).
- Shafer, A.; Dazzi, F. Meta-analysis of the positive and Negative Syndrome Scale (PANSS) factor structure. J. Psychiatr. Res. 2019, 115, 113–120. [Google Scholar] [CrossRef] [PubMed]
- Patlola, S.R.; Donohoe, G.; McKernan, D.P. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: A systematic review and meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2023, 121, 110668. [Google Scholar] [CrossRef]
- McCutcheon, R.A.; Keefe, R.S.E.; McGuire, P.K. Cognitive impairment in schizophrenia: Aetiology, pathophysiology, and treatment. Mol. Psychiatry 2023, 28, 1902–1918. [Google Scholar] [CrossRef]
- Chaumette, B.; Kebir, O.; Mam-Lam-Fook, C.; Morvan, Y.; Bourgin, J.; Godsil, B.P.; Plaze, M.; Gaillard, R.; Jay, T.M.; Krebs, M.-O. Salivary cortisol in early psychosis: New findings and meta-analysis. Psychoneuroendocrinology 2016, 63, 262–270. [Google Scholar] [CrossRef]
- Pompili, M.; Amador, X.F.; Girardi, P.; Harkavy-Friedman, J.; Harrow, M.; Kaplan, K.; Krausz, M.; Lester, D.; Meltzer, H.Y.; Modestin, J.; et al. Suicide risk in schizophrenia: Learning from the past to change the future. Ann. Gen. Psychiatry 2007, 6, 10. [Google Scholar] [CrossRef]
- Schonfeld, L.; Jaehne, E.J.; Ogden, A.R.; Spiers, J.G.; Hogarth, S.; van den Buuse, M. Differential effects of chronic adolescent glucocorticoid or methamphetamine on drug-induced locomotor hyperactivity and disruption of prepulse inhibition in adulthood in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2022, 117, 110552. [Google Scholar] [CrossRef]
- Mikulska, J.; Juszczyk, G.; Gawrońska-Grzywacz, M.; Herbet, M. HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation. Brain Sci. 2021, 11, 1298. [Google Scholar] [CrossRef] [PubMed]
- Gellman, M.D. Encyclopedia of Behavioral Medicine. Available online: https://link.springer.com/referencework/10.1007/978-1-4419-1005-9 (accessed on 15 June 2024).
- Mondelli, V.; Dazzan, P.; Hepgul, N.; Di Forti, M.; Aas, M.; D’Albenzio, A.; Di Nicola, M.; Fisher, H.; Handley, R.; Marques, T.R.; et al. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116, 234–242. [Google Scholar] [CrossRef] [PubMed]
- Mondelli, V.; Dazzan, P.; Gabilondo, A.; Tournikioti, K.; Walshe, M.; Marshall, N.; Schulze, K.K.; Murray, R.M.; McDonald, C.; Pariante, C.M. Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder. Psychoneuroendocrinology 2008, 33, 1004–1012. [Google Scholar] [CrossRef] [PubMed]
- Nasib, L.G.; Gangadin, S.S.; Rossum, I.W.-v.; Boudewijns, Z.S.R.M.; de Witte, L.D.; Wilting, I.; Luykx, J.; Somers, M.; Veen, N.; van Baal, C.; et al. The effect of prednisolone on symptom severity in schizophrenia: A placebo-controlled, randomized controlled trial. Schizophr. Res. 2021, 230, 79–86. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.-J.; Chao, Y.-L.; Chen, C.-Y.; Chang, C.-M.; Wu, E.C.-H.; Wu, C.-S.; Yeh, H.-H.; Chen, C.-H.; Tsai, H.-J. Prevalence of autoimmune diseases in in-patients with schizophrenia: Nationwide population-based study. Br. J. Psychiatry 2012, 200, 374–380. [Google Scholar] [CrossRef] [PubMed]
- Benros, M.E.; Pedersen, M.G.; Rasmussen, H.; Eaton, W.W.; Nordentoft, M.; Mortensen, P.B. A Nationwide Study on the Risk of Autoimmune Diseases in Individuals With a Personal or a Family History of Schizophrenia and Related Psychosis. Am. J. Psychiatry 2014, 171, 218–226. [Google Scholar] [CrossRef]
- Zheng, W.; Cai, D.-B.; Yang, X.-H.; Ungvari, G.S.; Ng, C.H.; Müller, N.; Ning, Y.-P.; Xiang, Y.-T. Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. J. Psychiatr. Res. 2017, 92, 139–146. [Google Scholar] [CrossRef]
- Kayser, M.S.; Dalmau, J. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr. Res. 2016, 176, 36–40. [Google Scholar] [CrossRef]
- Khlidj, Y.; Haireche, M.A. Schizophrenia as autoimmune disease: Involvement of Anti-NCAM antibodies. J. Psychiatr. Res. 2023, 161, 333–341. [Google Scholar] [CrossRef]
- Meijer, O.C.; de Lange, E.C.M.; Breimer, D.D.; de Boer, A.G.; Workel, J.O.; de Kloet, E.R. Penetration of Dexamethasone into Brain Glucocorticoid Targets Is Enhanced in mdr1A P-Glycoprotein Knockout Mice*. Endocrinology 1998, 139, 1789–1793. [Google Scholar] [CrossRef]
- Karssen, A.M.; Meijer, O.C.; de Kloet, E.R. Corticosteroids and the blood–brain barrier. Tech. Behav. Neural Sci. 2005, 15, 329–340. [Google Scholar] [CrossRef]
- Fietta, P.; Fietta, P.; Delsante, G. Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin. Neurosci. 2009, 63, 613–622. [Google Scholar] [CrossRef]
- Wang, W.-C.; Lu, M.-L.; Chen, V.C.-H.; Ng, M.-H.; Huang, K.-Y.; Hsieh, M.-H.; Hsieh, M.-J.; McIntyre, R.S.; Lee, Y.; Lee, C.T.-C. Asthma, corticosteroid use and schizophrenia: A nationwide population-based study in Taiwan. PLoS ONE 2017, 12, e0173063. [Google Scholar] [CrossRef] [PubMed]
- Broberg, B.V.; Sommer, I.E.; Benros, M.E.; Glenthøj, B.Y.; Gasse, C.; Köhler-Forsberg, O. Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence—A Danish nationwide study. Schizophr. Res. 2018, 199, 116–122. [Google Scholar] [CrossRef] [PubMed]
- Fiks, G.; Duarte, J.M.; Lisi, G.R.; Garro, M.; Appiani, F. Psychotic Symptoms After SARS-CoV-2 Infection. J. Nerv. Ment. Dis. 2022, 210, 724–726. [Google Scholar] [CrossRef]
- Steimer, T. The biology of fear- and anxiety-related behaviors. Dialogues Clin. Neurosci. 2002, 4, 231–249. [Google Scholar] [CrossRef]
- Penninx, B.W.; Pine, D.S.; Holmes, E.A.; Reif, A. Anxiety disorders. Lancet 2021, 397, 914–927. [Google Scholar] [CrossRef]
- Moreland-Capuia, A.R.; Vahabzadeh, A.; Gillespie, C.F.; Ressler, K.J. Chapter 44—Fear-related anxiety disorders and posttraumatic stress disorder. In Neurobiology of Brain Disorders, 2nd ed.; Zigmond, M.J., Wiley, C.A., Chesselet, M.-F., Eds.; Academic Press: Cambridge, MA, USA, 2023; pp. 811–824. [Google Scholar]
- National Institute of Mental Health. Anxiety Disorders. Available online: https://www.nimh.nih.gov/health/topics/anxiety-disorders (accessed on 25 August 2024).
- Dee, G.; Ryznar, R.; Dee, C. Epigenetic Changes Associated with Different Types of Stressors and Suicide. Cells 2023, 12, 1258. [Google Scholar] [CrossRef]
- Martin, E.I.; Ressler Kj Fau-Binder, E.; Binder E Fau-Nemeroff, C.B.; Nemeroff, C.B. The neurobiology of anxiety disorders: Brain imaging, genetics, and psychoneuroendocrinology. Psychiatr. Clin. N. Am. 2013, 32, 549–575. [Google Scholar] [CrossRef]
- Beauregard, M. Functional neuroimaging studies of the effects of psychotherapy. Dialogues Clin. Neurosci. 2014, 16, 75–81. [Google Scholar] [CrossRef] [PubMed]
- Marwood, L.; Wise, T.; Perkins, A.M.; Cleare, A.J. Meta-analyses of the neural mechanisms and predictors of response to psychotherapy in depression and anxiety. Neurosci. Biobehav. Rev. 2018, 95, 61–72. [Google Scholar] [CrossRef] [PubMed]
- World Health Organisation (WHO). Mental Disorders Article. Available online: https://www.who.int/news-room/fact-sheets/detail/mental-disorders/?gclid=CjwKCAiA75itBhA6EiwAkho9e5GMkI1GhOdiMegpMrSVoM-07Cj8J3ku8NnTU54iT9vSkwLnh0bfFhoCf70QAvD_BwE (accessed on 10 April 2024).
- Javaid, S.F.; Hashim, I.J.; Hashim, M.J.; Stip, E.; Samad, M.A.; Ahbabi, A.A. Epidemiology of anxiety disorders: Global burden and sociodemographic associations. Middle East. Curr. Psychiatry 2023, 30, 44. [Google Scholar] [CrossRef]
- Korte, S.M. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci. Biobehav. Rev. 2001, 25, 117–142. [Google Scholar] [CrossRef] [PubMed]
- Spencer, R.L.; Deak, T. A users guide to HPA axis research. Physiol. Behav. 2017, 178, 43–65. [Google Scholar] [CrossRef]
- Leistner, C.; Menke, A. Hypothalamic–pituitary–adrenal axis and stress. Handb. Clin. Neurol. 2020, 175, 55–64. [Google Scholar]
- De Kloet, E.R.; Joëls, M.; Holsboer, F. Stress and the brain: From adaptation to disease. Nat. Rev. Neurosci. 2005, 6, 463–475. [Google Scholar] [CrossRef]
- Mourtzi, N.; Sertedaki, A.; Charmandari, E. Glucocorticoid signaling and epigenetic alterations in stress-related disorders. Int. J. Mol. Sci. 2021, 22, 5964. [Google Scholar] [CrossRef]
- Gądek-Michalska, A.; Spyrka, J.; Rachwalska, P.; Tadeusz, J.; Bugajski, J. Influence of chronic stress on brain corticosteroid receptors and HPA axis activity. Pharmacol. Rep. 2013, 65, 1163–1175. [Google Scholar] [CrossRef]
- Packard, A.E.; Egan, A.E.; Ulrich-Lai, Y.M. HPA axis-interaction with behavioral systems. Compr. Physiol. 2016, 6, 1897. [Google Scholar]
- Kapugi, M.; Cunningham, K. Corticosteroids. Orthop. Nurs. 2019, 38, 336–339. [Google Scholar] [CrossRef] [PubMed]
- Alturaymi, M.A.; Almadhi, O.F.; Alageel, Y.S.; Dayel, M.B.; Alsubayyil, M.S.; Alkhateeb, B.F. The Association Between Prolonged Use of Oral Corticosteroids and Mental Disorders: Do Steroids Have a Role in Developing Mental Disorders? Cureus 2023, 15, e37627. [Google Scholar] [CrossRef] [PubMed]
- Karssen, A.M.; de Kloet, E.R. Synthetic Glucocorticoids. In Encyclopedia of Stress, 2nd ed.; Fink, G., Ed.; Academic Press: New York, NY, USA, 2007; pp. 704–708. [Google Scholar]
- Warrington, T.P.; Bostwick, J.M. Psychiatric adverse effects of corticosteroids. Mayo Clin. Proc. 2006, 81, 1361–1367. [Google Scholar]
- Yagi, Y.; Takahashi, Y.; Ogata, Y.; Yamana, H.; Kumakura, Y.; Ichihashi, K.; Kasai, K.; Kondo, S. Oral corticosteroid dosage and clinical presentation of psychiatric conditions after steroid use: A consultation-liaison psychiatry service’s experience. Neuropsychopharmacol. Rep. 2021, 41, 471–475. [Google Scholar] [CrossRef] [PubMed]
- Jorge, R.E. Posttraumatic stress disorder. Behav. Neurol. Neuropsychiatry 2015, 21, 789–805. [Google Scholar] [CrossRef] [PubMed]
- Resick, P.A.; Monson, C.M.; LoSavio, S.T. Posttraumatic Stress Disorder. In Psychopathology: History, Diagnosis, and Empirical Foundations, 3rd ed.; Wiley: Hoboken, NJ, USA, 2017; pp. 216–261. [Google Scholar]
- Pai, A.; Suris, A.M.; North, C.S. Posttraumatic stress disorder in the DSM-5: Controversy, change, and conceptual considerations. Behav. Sci. 2017, 7, 7. [Google Scholar] [CrossRef]
- Ressler, K.J.; Berretta, S.; Bolshakov, V.Y.; Rosso, I.M.; Meloni, E.G.; Rauch, S.L.; Carlezon Jr, W.A. Post-traumatic stress disorder: Clinical and translational neuroscience from cells to circuits. Nat. Rev. Neurol. 2022, 18, 273–288. [Google Scholar] [CrossRef]
- Sherin, J.E.; Nemeroff, C.B. Post-traumatic stress disorder: The neurobiological impact of psychological trauma. Dialogues Clin. Neurosci. 2011, 13, 263–278S. [Google Scholar] [CrossRef]
- Snyder, A.E.; Silberman, Y. Corticotropin releasing factor and norepinephrine related circuitry changes in the bed nucleus of the stria terminalis in stress and alcohol and substance use disorders. Neuropharmacology 2021, 201, 108814. [Google Scholar] [CrossRef]
- Pereira, R.F.; Alvarenga, M. Disordered eating: Identifying, treating, preventing, and differentiating it from eating disorders. Diabetes Spectr. 2007, 20, 141–148. [Google Scholar] [CrossRef]
- Dabbah-Assadi, F.; Handel, R.; Shamir, A. What we know about the role of corticosteroids in psychiatric disorders; evidence from animal and clinical studies. J. Psychiatr. Res. 2022, 155, 363–370. [Google Scholar] [CrossRef]
- Treasure, J.; Duarte, T.A.; Schmidt, U. Eating disorders. Lancet 2020, 395, 899–911. [Google Scholar] [CrossRef] [PubMed]
- Aparicio-Martinez, P.; Perea-Moreno, A.J.; Martinez-Jimenez, M.P.; Redel-Macías, M.D.; Pagliari, C.; Vaquero-Abellan, M. Social Media, Thin-Ideal, Body Dissatisfaction and Disordered Eating Attitudes: An Exploratory Analysis. Int. J. Env. Res. Public Health 2019, 16, 4177. [Google Scholar] [CrossRef]
- Smink, F.R.E.; van Hoeken, D.; Hoek, H.W. Epidemiology of eating disorders: Incidence, prevalence and mortality rates. Curr. Psychiatry Rep. 2012, 14, 406–414. [Google Scholar] [CrossRef] [PubMed]
- Misra, M.; Klibanski, A. Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol. 2014, 2, 581–592. [Google Scholar] [CrossRef] [PubMed]
- Kuckuck, S.; van der Valk, E.S.; Scheurink, A.J.W.; van der Voorn, B.; Iyer, A.M.; Visser, J.A.; Delhanty, P.J.D.; van den Berg, S.A.A.; van Rossum, E.A.-O. Glucocorticoids, stress and eating: The mediating role of appetite-regulating hormones. Obes. Rev. 2023, 24, e13539. [Google Scholar] [CrossRef] [PubMed]
- Niebrzydowska, A.; Grabowski, J. Medication-Induced Psychotic Disorder. A Review Of Selected Drugs Side Effects. Psychiatr. Danub. 2022, 34, 11–18. [Google Scholar] [CrossRef]
- Huynh, G.; Reinert, J.P. Pharmacological Management of Steroid-Induced Psychosis: A Review of Patient Cases. J. Pharm. Technol. 2021, 37, 120–126. [Google Scholar] [CrossRef]
- Veronese, N.; Demurtas, J.; Yang, L.; Tonelli, R.; Barbagallo, M.; Lopalco, P.; Lagolio, E.; Celotto, S.; Pizzol, D.; Zou, L.; et al. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Front. Med. 2020, 7, 170. [Google Scholar] [CrossRef]
- Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020, 395, 473–475. [Google Scholar] [CrossRef]
- Almilaibary, A. Using Telemedicine in Saudi Arabia’s Healthcare System During COVID-19 Pandemic. Jordan. J. Appl. Sci.-Nat. Sci. Ser. 2023, 17, 5–9. [Google Scholar]
- Raju, R.V.P.; Biatris, P.S. Therapeutic role of corticosteroids in COVID-19: A systematic review of registered clinical trials. Future J. Pharm. Sci. 2021, 7, 67. [Google Scholar] [CrossRef] [PubMed]
- Kozato, N.; Mishra, M.; Firdosi, M. New-onset psychosis due to COVID-19. BMJ Case Rep. 2021, 14, e242538. [Google Scholar] [CrossRef] [PubMed]
- Catalán, I.P.; Martí, C.R.; Sota, D.P.d.l.; Álvarez, A.C.; Gimeno, M.J.E.; Juana, S.F.; Rodríguez, G.H.; Bajo, E.D.; Gaya, N.T.; Blasco, J.U.; et al. Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission. J. Med. Virol. 2022, 94, 205–210. [Google Scholar] [CrossRef] [PubMed]
- Khalid, A.M.; Rashid, H.M.; Alsafi, M.A.; Munaim, A.A.; Afifi, F. Impact of COVID-19 pandemic on the plant-based food and supplement consumption of the Jordanians and Iraqis: A retrospective evaluation. Jordan. J. Appl. Sci. -Nat. Sci. Ser. 2024, 18, 41–49. [Google Scholar]
- Baldaçara, L.; Ramos, A.; Castaldelli-Maia, J.M. Managing drug-induced psychosis. Int. Rev. Psychiatry 2023, 35, 496–502. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nasereddin, L.; Alnajjar, O.; Bashar, H.; Abuarab, S.F.; Al-Adwan, R.; Chellappan, D.K.; Barakat, M. Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications. Diseases 2024, 12, 300. https://doi.org/10.3390/diseases12120300
Nasereddin L, Alnajjar O, Bashar H, Abuarab SF, Al-Adwan R, Chellappan DK, Barakat M. Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications. Diseases. 2024; 12(12):300. https://doi.org/10.3390/diseases12120300
Chicago/Turabian StyleNasereddin, Lara, Omar Alnajjar, Homam Bashar, Sara Feras Abuarab, Rahma Al-Adwan, Dinesh Kumar Chellappan, and Muna Barakat. 2024. "Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications" Diseases 12, no. 12: 300. https://doi.org/10.3390/diseases12120300
APA StyleNasereddin, L., Alnajjar, O., Bashar, H., Abuarab, S. F., Al-Adwan, R., Chellappan, D. K., & Barakat, M. (2024). Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications. Diseases, 12(12), 300. https://doi.org/10.3390/diseases12120300